Safety & Efficacy of Fecal Microbiome Transplantation (FMT) in

Status Terminated

Clinical Trial Summary

Antibiotic dependent pouchitis (ADP) is predestined to benefit from FMT, since bacterial dysbiosis, which can only be controlled with antibiotics, appears to be the major driver of the clinical symptoms. This is a proof of concept randomized placebo controlled trial, in which 50% of the patients will receive FMT and 50% will receive a placebo FMT. Additionally the trial offers an open label extension period.

Clinical Trial Description

FMT for ADP is a promising approach, given the documented role of bacteria in the pathogenesis. In contrast to patients with C. difficile colitis, in whom a single FMT is highly effective, in patients with Inflammatory Bowel Disease (IBD) an intensified therapy with daily or repeated FMT may be more beneficial. Whereas repeated endoscopic application are not feasible and repeated enema applications are not favored by patients a combination of endoscopic FMT and consecutive maintenance therapy with oral FMT using the FMT capsule G3 produced by OpenBiome to help establish the donor microbiome in the host seems to be the most promising approach. The objective of this trial is to evaluate the safety of FMT in patients with ADP and to estimate the effect size to be achieved from FMT therapy in patients with ADP for subsequent evaluation in a large definitive trial. A secondary objective is to study the microbial engraftment of donor FMT in the recipients.

This proof of concept randomized placebo controlled trial with an open label extension period will evaluate the safety and efficacy of an initial endoscopic FMT followed by 14 days of oral FMT. The study has two distinct outcomes, a clinical and translational aim, to investigate the effect of FMT in patients with ADP.

Aim1: Evaluation of safety, tolerability and clinical effectiveness (measured as clinical response or remission and discontinuation of antibiotic therapy) of FMT in patients with ADP.

Aim 2: Evaluation of the impact of FMT on the fecal bacterial microbiome in patients with ADP, which will provide functional data about possible mechanisms of this therapy. ;

Study Design

Related Conditions & MeSH terms

Pouchitis

Clinical Trial Details

NCT number	NCT02782325
Study type	Interventional
Source	University of North Carolina, Chapel Hill
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	June 1, 2017
Completion date	December 3, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04979832` - GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery	Phase 1/Phase 2
Terminated	`NCT00061282` - Clotrimazole Enemas for Pouchitis in Children and Adults	Phase 1/Phase 2
Not yet recruiting	`NCT05829109` - Fecal Microbiota Transplant for Patients With Chronic Pouchitis	Early Phase 1
Recruiting	`NCT03136419` - Microbiota and Immune microEnvironment in Pouchitis	N/A
Withdrawn	`NCT04640155` - Treating Chronic Pouchitis With a Low FODMAP Diet	N/A
Completed	`NCT02201186` - To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis	Phase 2
Completed	`NCT02790138` - A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis	Phase 4
Not yet recruiting	`NCT01202396` - The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis	N/A
Completed	`NCT02428361` - Fecal Microbiota Transplant (FMT) for Pouchitis	Early Phase 1
Completed	`NCT03538366` - Fecal Microbiota Transplantation for Chronic Pouchitis	N/A
Completed	`NCT04763564` - Efficacy of Liraglutide Therapy in Patients With IPAA	Phase 2
Terminated	`NCT00583531` - Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis	Phase 2
Recruiting	`NCT03524352` - the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis	Phase 3
Completed	`NCT04820413` - Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis	N/A
Recruiting	`NCT04089345` - Stelara fOr ChRonic AntibioTic rEfractory pouchitiS	Phase 3
Not yet recruiting	`NCT03526796` - Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis	N/A
Completed	`NCT02828410` - Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA	N/A
Recruiting	`NCT05578313` - Inflammatory Bowel Diseases (IBD) Cannabis Registry
Not yet recruiting	`NCT06316999` - Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis	N/A
Terminated	`NCT04100291` - Faecal Microbiota Transplantation in the Treatment of Chronic Pouchitis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms